Sort by
Refine Your Search
-
Listed
-
Category
-
Employer
- ;
- University of Nottingham
- Nature Careers
- UNIVERSITY OF SOUTHAMPTON
- University of Leeds
- CRANFIELD UNIVERSITY
- UNIVERSITY OF MELBOURNE
- University of Birmingham
- SINGAPORE INSTITUTE OF TECHNOLOGY (SIT)
- University of Oxford
- KINGS COLLEGE LONDON
- The University of Southampton
- King's College London
- University of Cambridge
- University of Glasgow
- University of London
- University of the West of England
- ; Queen Mary University of London
- ; University of Copenhagen
- ; University of Oxford
- Aston University
- Birmingham City University
- Brunel University
- CZECH UNIVERSITY OF LIFE SCIENCES
- City University London
- Cranfield University
- Manchester Metropolitan University
- UNIVERSITY OF SURREY
- University College London
- University of Hull
- University of Leicester
- University of Surrey
- 22 more »
- « less
-
Field
-
Fixed Term until 31/03/2026 The University of Southampton is committed to excellence in all we do, applying our insights and inventiveness to solve complex engineering and environmental challenges
-
to an exciting new effort to accelerate and miniaturise micro-elasticity imaging systems for in-vivo and clinical applications. You will be part of a dynamic, interdisciplinary team aiming
-
siteAvailable for SecondmentNoClosing Date09-Jul-2025 University College London Hospitals is the largest cellular therapy service in the United Kingdom. It is at the forefront of delivering innovative and life
-
future generations. The Department comprises more than 25 research groups, working at every level of biological organization from genes to ecosystems. We are keen to increase diversity in our academic
-
. This group uses state-of-the-art Earth observation data and advanced computer techniques to study the Polar regions. We specialise in using Synthetic Aperture Radar (SAR) and altimetry satellite data
-
is one of the top 80 universities in the world. We have a truly global community, with more than 39,000 students from 170 different countries and over 9,000 staff of 100 different nationalities
-
essential for the development of targeted therapeutics. Using interdisciplinary approaches, we have identified and characterised atypical E3 ligases such as MYCBP2 and RNF213. MYCBP2 is a key regulator of
-
studies, and sustainable development. With over 18,000 students and a strong international community, CZU is a dynamic and modem institution committed to excellence in research, innovation, and education
-
work with the Cambridge-GSK Translational Immunology Collaboration (https://www.med.cam.ac.uk/cg-tic ). This is a new interdisciplinary partnership between the University of Cambridge and GSK, bringing
-
molecular and structural mechanisms is essential for therapeutic development. Using E3 activity-based chemical probes, we have substantially expanded the known landscape of E3 ligase subtypes—effectively